Literature DB >> 32217776

Differential clinicopathological features of EGPA-associated neuropathy with and without ANCA.

Ryoji Nishi1, Haruki Koike2, Ken Ohyama1, Yuki Fukami1, Shohei Ikeda1, Yuichi Kawagashira1, Masahiro Iijima1, Masahisa Katsuno1, Gen Sobue2.   

Abstract

OBJECTIVE: To investigate the clinicopathologic features of eosinophilic granulomatosis with polyangiitis (EGPA)-associated neuropathy with a focus on the presence or absence of anti-neutrophil cytoplasmic antibodies (ANCAs).
METHODS: We examined the clinical features and pathologic findings of sural nerve biopsy specimens from 82 patients with EGPA-associated neuropathy. Of these patients, 32.9% were myeloperoxidase (MPO)-ANCA positive, and 67.1% were MPO-ANCA negative. PR3-ANCA was negative in all of 78 examined patients.
RESULTS: Upper limb symptoms were more frequently reported as initial neuropathic manifestations in the MPO-ANCA-positive group than in the MPO-ANCA-negative group (44.4% vs 14.6%, p < 0.01). The serum levels of C-reactive protein were significantly higher in the MPO-ANCA-positive group than in the MPO-ANCA-negative group (p < 0.05). Sural nerve biopsy specimens showed findings suggestive of vasculitis (i.e., destruction of vascular structures) in epineurial vessels; these results were seen more frequently in the MPO-ANCA-positive group than in the MPO-ANCA-negative group (p < 0.0001). Conversely, the numbers of eosinophils in the lumen of the epineurial vessels (p < 0.01) and epineurial vessels occluded by intraluminal eosinophils (p < 0.05) were higher in the MPO-ANCA-negative group than in the MPO-ANCA-positive group. Furthermore, the incidence of eosinophil infiltration in the endoneurium was higher in the MPO-ANCA-negative group than in the MPO-ANCA-positive group (p < 0.01).
CONCLUSIONS: This study suggests that the pathogenesis of EGPA comprises at least 2 distinct mechanisms: ANCA-associated vasculitis resulting in ischemic effects and inflammation, which is prominent in MPO-ANCA-positive patients, and eosinophil-associated vascular occlusion leading to ischemia and eosinophil-associated tissue damage, which is conspicuous in MPO-ANCA-negative patients.
© 2020 American Academy of Neurology.

Entities:  

Year:  2020        PMID: 32217776     DOI: 10.1212/WNL.0000000000009309

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Haruki Koike; Ryoji Nishi; Satoru Yagi; Soma Furukawa; Yuki Fukami; Masahiro Iijima; Masahisa Katsuno
Journal:  Adv Ther       Date:  2022-09-24       Impact factor: 4.070

2.  Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.

Authors:  Elizabeth A Jacobsen; David J Jackson; Enrico Heffler; Sameer K Mathur; Albert J Bredenoord; Ian D Pavord; Praveen Akuthota; Florence Roufosse; Marc E Rothenberg
Journal:  Annu Rev Immunol       Date:  2021-03-01       Impact factor: 28.527

3.  Eosinophil ETosis-Mediated Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis.

Authors:  Mineyo Fukuchi; Yosuke Kamide; Shigeharu Ueki; Yui Miyabe; Yasunori Konno; Nobuyuki Oka; Hiroki Takeuchi; Souichi Koyota; Makoto Hirokawa; Takechiyo Yamada; Rossana C N Melo; Peter F Weller; Masami Taniguchi
Journal:  Arthritis Rheumatol       Date:  2021-08-11       Impact factor: 15.483

4.  Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.

Authors:  Ivan Medvedev; Valery I Podzolkov; Tatiana I Ishina; Mikhail V Pisarev
Journal:  Am J Case Rep       Date:  2021-02-14

Review 5.  Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology.

Authors:  Filippo Fagni; Federica Bello; Giacomo Emmi
Journal:  Front Med (Lausanne)       Date:  2021-02-24

6.  Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and Immunothrombosis.

Authors:  Teppei Hashimoto; Shigeharu Ueki; Yosuke Kamide; Yui Miyabe; Mineyo Fukuchi; Yuichi Yokoyama; Tetsuya Furukawa; Naoto Azuma; Nobuyuki Oka; Hiroki Takeuchi; Kyoko Kanno; Akemi Ishida-Yamamoto; Masami Taniguchi; Akira Hashiramoto; Kiyoshi Matsui
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

7.  Eosinophilic granulomatosis with polyangiitis presenting with repetitive acute coronary syndrome, refractory coronary vasospasm, and spontaneous coronary dissection: a case report.

Authors:  Maohuan Lin; Zizhuo Su; Jianzhong Huang; Jiajie Li; Niansang Luo; Jingfeng Wang
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

8.  Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab.

Authors:  Yoshiro Kai; Masanori Yoshikawa; Masayuki Matsuda; Kentaro Suzuki; Hiroya Ohara; Naohiko Iguchi; Takehito Kasamatsu; Kenji Uno; Nobuhiro Fujioka; Yukio Fujita; Shigeo Muro
Journal:  Allergy Asthma Clin Immunol       Date:  2022-02-19       Impact factor: 3.406

9.  Relationship Between Gender and 1-Year Mortality in ANCA-Associated Vasculitis Patients: A Single-Center Retrospective Analysis and Meta-Analysis.

Authors:  Qing Zhu; Fen Li; Xi Xie; Bilin Chen; Qianwen Yu; Yusong Wei; Yan Ge
Journal:  Front Med (Lausanne)       Date:  2022-07-13

Review 10.  ANCA-Associated Vasculitic Neuropathies: A Review.

Authors:  Haruki Koike; Ryoji Nishi; Ken Ohyama; Saori Morozumi; Yuichi Kawagashira; Soma Furukawa; Naohiro Mouri; Yuki Fukami; Masahiro Iijima; Gen Sobue; Masahisa Katsuno
Journal:  Neurol Ther       Date:  2022-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.